Diabetic dyslipidaemia and the atherosclerosis;Diabeteses dyslipidaemia és atherosclerosis

Orvosi Hetilap

Volumn 157, Issue 19, 2016, Pages 746-752

  Márk, László ^a   Dani, Győző ^a  

^a Bekes Megyei Kepviselotestulet Pandy Kalman Korhaz   (Hungary)

Author keywords

Cardiovascular risk; Diabetes mellitus; Diabetic dyslipidaemia; Statin fibrate

Indexed keywords

APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; APOA5 PROTEIN, HUMAN; APOLIPOPROTEIN A; APOLIPOPROTEIN C; LIPOPROTEIN; LIPOPROTEIN TRIGLYCERIDE;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIET RESTRICTION; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; INCIDENCE; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LOSS OF FUNCTION MUTATION; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OBESITY; PROTEIN METABOLISM; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; RISK FACTOR;

APOLIPOPROTEINS A; APOLIPOPROTEINS C; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FENOFIBRATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; LIPOPROTEIN LIPASE; LIPOPROTEINS; METABOLIC SYNDROME X; OBESITY; PREDICTIVE VALUE OF TESTS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TRIGLYCERIDES;

EID: 84967048401     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/650.2016.30441     Document Type: Article

References (36)

1. Zimmet, P. Z., Magliano, D. J., Herman, W. H., et al.: Diabetes: A 21st century challenge. Lancet Diabetes Endocrinol., 2014, 2(1), 56-64.
2. Shaw, J. E., Sicree, R. A., Zimmet, P. Z.: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract., 2010, 87(1), 4-14.
3. Jermendy, G., Nádas, J., Szigethy, E., et al.: Prevalence rate of diabetes mellitus and impaired fasting glycemia in Hungary: cross-sectional study on nationally representative sample of people aged 20-69 years. Croat. Med. J., 2010, 51(2), 151-156.
4. Danaei, G., Finucane, M. M., Lu, Y., et al.: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet, 2011, 378(9785), 31-40.
5. Emerging Risk Factors Collaboration, Sarwar, N., Gao, P., Seshasai, S. R., et al.: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet, 2010, 375(9733), 2215- 2222.
6. Chait, A., Bierman, E. L.: Pathogenesis of macrovascular disease in diabetes. In: Kahn, C. R., Weir, G. C. (eds.): Joslin's diabetes mellitus. 13th edition. Lea and Febiger, Philadelphia, 1994.
7. Márk, L., Kiss, Z., Nagy, L., et al.: Beyond decreasing LDL-cholesterol: changes in HDL-cholesterol and trigliceride in patients with high risk. [Az LDL-koleszterin-szint csökkentésen túl: A HDL-koleszterin- és trigliceridszintek alakulása nagy kockázatú betegek körében.] Metabolizmus, 2009, 7(1), 33-38. [Hungarian].
8. Isomaa, B., Almgren, P., Tuomi, T., et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001, 24(4), 683-689.
9. Feher, M., Greener, M., N. Munro, N.: Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus. Diabetes Metab. Syndr. Obes., 2013, 6, 11-15.
10. Leiter, L. A., Lundman, P., da Silva, P. M., et al.: Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: Results of the Dyslipidaemia International Study. Diabet. Med., 2011, 28(11), 1343-1351.
11. Taskinen, M. R., Borén, J.: New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis, 2015, 239(2), 483-495.
12. Do, R., Stitziel, N. O., Won, H. H., et al.: Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature, 2015, 518(7537), 102-106.
13. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Crosby, J., Peloso, G. M., Auer, P. L., et al.: Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med., 2014, 371(1), 22-31.
14. Varbo, A., Benn, M., Tybjærg-Hansen, A., et al.: Remnant cholesterol as a causal risk factor for ischemic heart disease. J. Am. Coll. Cardiol., 2013, 61(4), 427-436.
15. McPherson, R.: Remnant cholesterol: "Non-(HDL-C + LDL-C)" as a coronary artery disease risk factor. J. Am. Coll. Cardiol., 2013, 61(4), 437-439.
16. Boekholdt, S. M., Arsenault, B. J., Mora, S., et al.: Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A meta-analysis. JAMA, 2012, 307(12), 1302-1309.
17. Márk, L., Reiber, I., Paragh, Gy., et al.: Importance of non-HDL-cholesterol determination in diabetic patients. [A non-HDL-koleszterin vizsgálatának jelentosége cukorbetegekben.] Metabolizmus, 2012, 10(5), 285-292. [Hungarian].
18. Mark, L., Vallejo-Vaz, A. J., Reiber, I., et al.: Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2, 674 individuals in Hungary. Atherosclerosis, 2015, 241(1), 62-68.
19. Reiber, I., Paragh, Gy., Márk, L., et al.: The most atherogenic cholesterol. [Az igazán atherogen koleszterin.] Metabolizmus, 2011, 9(3), 146-150. [Hungarian].
20. Reiber, I., Mezo, I., Mark, L., et al.: The good, the bad, and the atherogenic. Letter to the editor. J. Am. Coll. Cardiol., 2012, 59(14), 1333-1334.
21. Reiner, Z., Catapano, A. L., De Backer, G., et al., The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS): ESC/EAS Guidelines for the management of dyslipidaemias. Eur. Heart J., 2011, 32(14), 1769-1818.
22. Jacobson, T. A., Ito, M. K., Maki, K. C., et al.: National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 - executive summary. J. Clin. Lipidol., 2014, 8(5), 473-488.
23. Recommendations of the 6th Hungarian Cardiovascular Consensus Conference. [A VI. Magyar Kardiovaszkuláris Konszenzus Konferencia ajánlásai.] Metabolizmus, 2015, 13(1), 1-55. [Hungarian].
24. Gaede, P., Lund-Andersen, H., Parving, H. H., et al.: Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med., 2008, 358(6), 580-591.
25. Yudkin, J. S., Richter, B., Gale, E. A.: Intensified glucose lowering in type 2 diabetes: Time for a reappraisal. Diabetologia, 2010, 53(10), 2079-2085.
26. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney, P. M., Blackwell, L., Collins, R., et al.: Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet, 2008, 371(9607), 117- 125.
27. Sattar, N., Preiss, D., Murray, H. M., et al.: Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet, 2010, 375(9716), 735-742.
28. Preiss, D., Seshasai, S. R., Welsh, P., et al.: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA, 2011, 305(24), 2556-2564.
29. Van de Woestijne, A. P., van der Graaf, Y., Westerink, J., et al.: Effect of statin therapy on incident type 2 diabetes mellitus in patients with clinically manifest vascular disease. Am. J. Cardiol., 2015, 115(4), 441-446.
30. Bays, H. E.: Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus. Int. J. Gen. Med., 2014, 7, 355-364.
31. Cannon, C. P., Blazing, M. A., Giugliano, R. P., et al.: Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med., 2015, 372(25), 2387-2397.
32. ACCORD Study Group, Ginsberg, H. N., Elam, M. B., Lovato, L. C., et al.: Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med., 2010, 362(17), 1563-1574.
33. FDA Endocrinologic and Metabolic Drugs Advisory Committee meeting, May 19, 2011, Briefing information. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm255549.htm.
34. Tenenbaum, A., Fisman, E. Z.: Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc. Diabetol., 2012, 11, 125.
35. Sacks, F. M., Carey, V. J., Fruchart, J. C.: Combination lipid therapy in type 2 diabetes. N. Engl. J. Med., 2010, 363(7), 692- 694.
36. Aguiar, C., Alegria, E., Bonadonna, R. C., et al.: A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atheroscler. Suppl., 2015, 19, 1-12.